Hospital
Rideout Memorial Hospital
Rideout Memorial Hospital was paid $48.54M by Medicaid between Jan 2018 and Dec 2024, across 416 billing codes. Its largest line is 0450, Emergency room services — 11% of everything it billed.
33Billing provider infoRIDEOUT MEMORIAL HOSPITAL
MARYSVILLE, CA 95901
MARYSVILLE, CA 95901
33aNPI1720088354assigned 07/26/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.54M
24GClaims1,995,526
24DCodes billed416
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#63 of 410
Median peer was paid$6.90M
This provider vs. median7.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,218 | $5.17M | |
| 2019 | 228,950 | $5.17M | |
| 2020 | 183,168 | $4.49M | |
| 2021 | 243,115 | $6.63M | |
| 2022 | 369,449 | $9.18M | |
| 2023 | 417,391 | $10.29M | |
| 2024incomplete | 324,235 | $7.61M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 11% | 99,287 | 84,593 | $5.36M |
| 99199 | Unlisted special service, procedure or report | 6.4% | 59,010 | 48,969 | $3.08M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 13,274 | 12,960 | $2.19M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.7% | 21,908 | 20,529 | $1.80M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 17,093 | 16,459 | $1.74M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.4% | 21,615 | 18,756 | $1.67M |
| 80053 | Comprehensive metabolic panel | 2.8% | 131,828 | 107,226 | $1.36M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 48,832 | 43,943 | $1.17M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 161,715 | 128,031 | $916K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 35,554 | 8,515 | $892K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.8% | 5,266 | 5,205 | $870K |
| Z7502 | 1.8% | 23,083 | 22,300 | $870K |
404 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 17,283 | $852K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 12,300 | $805K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.5% | 13,058 | $741K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.5% | 10,411 | $735K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.4% | 11,229 | $700K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 26,158 | $663K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 3,988 | $648K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 6,430 | $637K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.3% | 4,165 | $636K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.2% | 17,238 | $587K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.1% | 23,682 | $544K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 54,353 | $531K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 25,398 | $501K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 22,422 | $482K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,367 | $457K |
| 83880 | <1% | 20,671 | $395K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,156 | $386K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,445 | $340K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 15,013 | $333K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,486 | $333K |
| J3490 | Unclassified drugs | <1% | 23,265 | $326K |
| 84484 | <1% | 38,399 | $325K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,497 | $312K |
| 97750 | <1% | 5,404 | $308K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 5,407 | $296K |
| 83690 | <1% | 40,430 | $291K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 9,306 | $285K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,936 | $284K |
| 76830 | Ultrasound, transvaginal | <1% | 4,504 | $282K |
| 0250 | <1% | 12,907 | $269K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 21,043 | $263K |
| 99283 | Emergency room visit (moderate) | <1% | 5,539 | $259K |
| 99284 | Emergency room visit (serious) | <1% | 5,079 | $256K |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 8,259 | $252K |
| 0270 | <1% | 22,556 | $245K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 32,839 | $245K |
| 59025 | Fetal non-stress test | <1% | 8,222 | $234K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,785 | $230K |
| 70486 | <1% | 1,209 | $225K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,807 | $224K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,920 | $220K |
| 99285 | Emergency room visit (most serious) | <1% | 4,158 | $209K |
| 93971 | <1% | 2,303 | $204K | |
| 76801 | <1% | 3,775 | $204K | |
| Z9725 | <1% | 4,659 | $200K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,501 | $174K |
| 97139 | <1% | 9,126 | $168K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,354 | $163K |
| 81001 | <1% | 56,745 | $159K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,860 | $154K |
| 71250 | <1% | 1,460 | $153K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,323 | $148K |
| 73610 | <1% | 6,058 | $147K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,492 | $147K |
| 73630 | <1% | 7,222 | $145K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 994 | $144K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 314 | $144K |
| 76770 | <1% | 1,979 | $140K | |
| 80143 | <1% | 4,713 | $140K | |
| 93017 | <1% | 2,585 | $139K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,846 | $139K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,578 | $138K |
| 73030 | <1% | 5,279 | $127K | |
| 0762 | <1% | 891 | $126K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,233 | $115K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,297 | $114K |
| 73130 | <1% | 4,245 | $111K | |
| 88307 | <1% | 1,487 | $110K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,132 | $106K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 304 | $106K |
| 73562 | <1% | 4,828 | $106K | |
| 87040 | <1% | 11,081 | $105K | |
| 72131 | <1% | 539 | $104K | |
| 93970 | <1% | 962 | $103K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 13 | $103K |
| 80179 | <1% | 4,615 | $102K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,845 | $98K |
| 73110 | <1% | 3,870 | $95K | |
| 82805 | <1% | 6,537 | $95K | |
| 80061 | Lipid panel | <1% | 10,292 | $89K |
| 90715 | <1% | 2,211 | $89K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 14,311 | $86K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 514 | $86K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,494 | $84K |
| 83605 | <1% | 12,316 | $83K | |
| 80076 | <1% | 9,240 | $80K | |
| 99070 | <1% | 56,519 | $79K | |
| 82962 | <1% | 10,597 | $76K | |
| 0637 | <1% | 10,443 | $71K | |
| 73502 | <1% | 1,884 | $66K | |
| 96367 | <1% | 1,701 | $66K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,685 | $63K |
| 73080 | <1% | 1,940 | $62K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 161 | $61K |
| 0510 | <1% | 1,994 | $60K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,805 | $60K |
| 97116 | <1% | 3,508 | $59K | |
| 83735 | <1% | 24,390 | $58K | |
| 84702 | <1% | 5,917 | $56K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,040 | $55K |
| 86900 | <1% | 8,716 | $54K | |
| 82803 | <1% | 3,500 | $53K | |
| 0729 | <1% | 1,419 | $52K | |
| 81003 | <1% | 20,989 | $52K | |
| 86850 | <1% | 5,392 | $52K | |
| 76870 | <1% | 906 | $51K | |
| 72100 | <1% | 1,653 | $50K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,994 | $50K |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,220 | $49K |
| 72110 | <1% | 986 | $48K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,068 | $46K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,303 | $46K |
| 73590 | <1% | 1,714 | $44K | |
| 84132 | <1% | 1,660 | $43K | |
| 86901 | <1% | 9,710 | $43K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 73 | $43K |
| 0360 | <1% | 306 | $42K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,630 | $41K |
| 81025 | <1% | 6,042 | $41K | |
| G0378 | Hospital observation service, per hour | <1% | 1,132 | $39K |
| 82330 | <1% | 5,812 | $39K | |
| 85610 | <1% | 14,771 | $37K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,203 | $37K |
| 87641 | <1% | 3,327 | $36K | |
| 0761 | <1% | 1,162 | $36K | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 113 | $36K |
| 73090 | <1% | 1,484 | $35K | |
| Z7610 | <1% | 10,436 | $34K | |
| 93880 | <1% | 330 | $34K | |
| 85027 | <1% | 9,201 | $34K | |
| 74018 | <1% | 2,079 | $33K | |
| 70491 | <1% | 146 | $32K | |
| 85730 | <1% | 7,343 | $32K | |
| 73564 | <1% | 936 | $31K | |
| 88304 | <1% | 1,792 | $31K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,127 | $31K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,073 | $30K |
| C1776 | Joint device (implantable) | <1% | 15 | $29K |
| 84703 | <1% | 12,502 | $29K | |
| 76536 | <1% | 420 | $28K | |
| 72040 | <1% | 989 | $28K | |
| 87186 | <1% | 6,183 | $28K | |
| 93226 | <1% | 525 | $27K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 287 | $27K |
| 84145 | <1% | 2,933 | $25K | |
| 87077 | <1% | 5,779 | $24K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 518 | $24K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,014 | $23K |
| 87081 | <1% | 3,636 | $23K | |
| 82728 | <1% | 2,675 | $22K | |
| 82550 | <1% | 4,418 | $22K | |
| 73560 | <1% | 1,249 | $22K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 112 | $22K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,187 | $21K |
| 93225 | <1% | 519 | $21K | |
| 84439 | <1% | 3,170 | $20K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 366 | $20K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 54 | $19K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,806 | $19K |
| 84466 | <1% | 2,602 | $19K | |
| 82948 | <1% | 5,640 | $18K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,334 | $18K |
| 73140 | <1% | 937 | $16K | |
| 86140 | <1% | 6,647 | $16K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,729 | $15K |
| 82746 | <1% | 1,776 | $15K | |
| 83970 | <1% | 638 | $15K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,529 | $14K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,620 | $14K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,094 | $14K |
| J2704 | Injection, propofol, 10 mg | <1% | 1,712 | $14K |
| 76857 | <1% | 314 | $14K | |
| 94729 | <1% | 305 | $13K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,762 | $13K |
| 82495 | <1% | 697 | $13K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 659 | $13K |
| 94060 | <1% | 320 | $13K | |
| 94664 | <1% | 586 | $13K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,593 | $13K |
| J1815 | Injection, insulin, per 5 units | <1% | 1,419 | $13K |
| 85007 | <1% | 6,494 | $12K | |
| 82553 | <1% | 684 | $12K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 25 | $12K |
| 83540 | <1% | 3,331 | $12K | |
| 94726 | <1% | 297 | $12K | |
| 0001A | <1% | 294 | $12K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,241 | $11K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,466 | $11K |
| 0683 | <1% | 80 | $11K | |
| 87400 | <1% | 1,123 | $10K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,655 | $9K |
| 82140 | <1% | 2,350 | $9K | |
| 72072 | <1% | 271 | $9K | |
| 12001 | <1% | 276 | $9K | |
| 87430 | <1% | 769 | $9K | |
| 0710 | <1% | 248 | $9K | |
| 97799 | <1% | 387 | $9K | |
| 85379 | <1% | 1,042 | $9K | |
| 73700 | <1% | 57 | $9K | |
| 87147 | <1% | 1,501 | $8K | |
| 94644 | <1% | 448 | $8K | |
| 86592 | <1% | 2,795 | $8K | |
| 84550 | <1% | 1,923 | $8K | |
| 73552 | <1% | 252 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 931 | $7K |
| 72128 | <1% | 49 | $7K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,387 | $7K |
| 01961 | <1% | 25 | $7K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 669 | $7K |
| 87631 | <1% | 112 | $7K | |
| 82247 | <1% | 2,420 | $7K | |
| 73120 | <1% | 316 | $6K | |
| 93242 | <1% | 414 | $6K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 614 | $6K |
| 82010 | <1% | 1,065 | $6K | |
| 0259 | <1% | 1,517 | $6K | |
| 72070 | <1% | 201 | $6K | |
| 72050 | <1% | 167 | $6K | |
| 87210 | <1% | 1,108 | $6K | |
| 82607 | <1% | 968 | $6K | |
| 10060 | <1% | 218 | $6K | |
| 84425 | <1% | 313 | $6K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 791 | $6K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 42 | $6K |
| 99253 | <1% | 114 | $5K | |
| 99152 | <1% | 148 | $5K | |
| 83615 | <1% | 1,391 | $5K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 260 | $5K |
| 97010 | <1% | 482 | $5K | |
| 72141 | <1% | 12 | $5K | |
| 84153 | <1% | 479 | $5K | |
| 85652 | <1% | 3,003 | $5K | |
| 84436 | <1% | 829 | $5K | |
| 86780 | <1% | 687 | $5K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 283 | $5K |
| 12011 | <1% | 74 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 111 | $4K |
| 59514 | <1% | 14 | $4K | |
| 86803 | <1% | 451 | $4K | |
| 73221 | <1% | 12 | $4K | |
| 0636 | <1% | 374 | $4K | |
| 73620 | <1% | 212 | $4K | |
| 77300 | <1% | 13 | $4K | |
| 29125 | <1% | 334 | $4K | |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | <1% | 328 | $4K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 819 | $4K |
| 84100 | <1% | 4,412 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 816 | $4K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 14 | $4K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 31 | $4K |
| 0011A | <1% | 87 | $3K | |
| 0760 | <1% | 130 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 626 | $3K |
| 96402 | <1% | 46 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 63 | $3K |
| 87088 | <1% | 1,072 | $3K | |
| 73600 | <1% | 75 | $3K | |
| 87340 | <1% | 599 | $3K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 92 | $3K |
| 82435 | <1% | 1,471 | $3K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 21 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 662 | $3K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 248 | $3K |
| 73100 | <1% | 137 | $3K | |
| 80074 | <1% | 251 | $3K | |
| 0002A | <1% | 70 | $3K | |
| 70498 | <1% | 39 | $3K | |
| 12002 | <1% | 87 | $3K | |
| 96417 | <1% | 167 | $3K | |
| 99254 | <1% | 41 | $3K | |
| 93270 | <1% | 72 | $3K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 66 | $3K |
| 86141 | <1% | 225 | $3K | |
| 94799 | <1% | 135 | $2K | |
| 87070 | <1% | 939 | $2K | |
| 80202 | <1% | 959 | $2K | |
| 73060 | <1% | 90 | $2K | |
| 0258 | <1% | 230 | $2K | |
| 87420 | <1% | 234 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 134 | $2K |
| 87205 | <1% | 1,310 | $2K | |
| 99499 | <1% | 39 | $2K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 433 | $2K |
| 72170 | <1% | 100 | $2K | |
| 88311 | <1% | 522 | $2K | |
| 87220 | <1% | 289 | $2K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 248 | $2K |
| 80069 | <1% | 957 | $2K | |
| 82947 | <1% | 896 | $2K | |
| 93925 | <1% | 26 | $2K | |
| 82800 | <1% | 176 | $2K | |
| 64445 | <1% | 24 | $2K | |
| 85651 | <1% | 491 | $2K | |
| 82652 | <1% | 48 | $2K | |
| 82043 | <1% | 524 | $2K | |
| 88313 | <1% | 34 | $2K | |
| X3908 | <1% | 48 | $1K | |
| 86762 | <1% | 246 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 112 | $1K |
| 30140 | <1% | 12 | $1K | |
| 97124 | <1% | 135 | $1K | |
| 82570 | <1% | 840 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 44 | $1K |
| 84481 | <1% | 135 | $1K | |
| 86923 | <1% | 194 | $1K | |
| 81513 | <1% | 12 | $1K | |
| 94150 | <1% | 106 | $1K | |
| 87149 | <1% | 50 | $1K | |
| 27447 | <1% | 13 | $1K | |
| 86038 | <1% | 137 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 323 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 25 | $1K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,880 | $994.57 |
| X3910 | <1% | 48 | $905.28 | |
| 88302 | <1% | 50 | $901.67 | |
| 87522 | Neg quan hep c or qual rna | <1% | 29 | $891.18 |
| 73070 | <1% | 38 | $860.71 | |
| 84630 | <1% | 87 | $859.04 | |
| 73660 | <1% | 43 | $797.34 | |
| 36600 | <1% | 201 | $786.36 | |
| 85520 | <1% | 348 | $771.73 | |
| 84403 | <1% | 42 | $767.40 | |
| 64447 | <1% | 29 | $763.75 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 263 | $744.80 |
| J7999 | Compounded drug, not otherwise classified | <1% | 26 | $722.28 |
| 97164 | <1% | 57 | $703.37 | |
| 82248 | <1% | 276 | $692.21 | |
| 88312 | <1% | 29 | $655.44 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $650.94 |
| 83631 | <1% | 30 | $619.73 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 13 | $617.31 |
| 82378 | <1% | 19 | $608.79 | |
| 74022 | <1% | 13 | $566.77 | |
| 73000 | <1% | 28 | $542.79 | |
| 93356 | <1% | 33 | $537.72 | |
| 72120 | <1% | 14 | $537.29 | |
| 82150 | <1% | 163 | $485.11 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 567 | $482.03 |
| 86300 | <1% | 25 | $462.50 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 13 | $439.78 |
| 84156 | <1% | 422 | $418.75 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 43 | $415.66 |
| 70496 | <1% | 12 | $397.93 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 30 | $397.67 |
| 83525 | <1% | 41 | $395.22 | |
| 86077 | <1% | 18 | $388.35 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 84 | $387.99 |
| 86431 | <1% | 98 | $381.17 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,024 | $369.60 |
| 31500 | <1% | 14 | $355.20 | |
| 86481 | <1% | 25 | $349.00 | |
| 88112 | <1% | 30 | $342.88 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 32 | $328.00 |
| 87481 | <1% | 12 | $308.70 | |
| 86880 | <1% | 312 | $301.62 | |
| 88142 | <1% | 18 | $299.40 | |
| 87075 | <1% | 171 | $288.98 | |
| 87493 | <1% | 45 | $252.12 | |
| 96415 | <1% | 13 | $242.28 | |
| 86708 | <1% | 31 | $227.85 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 17 | $199.30 |
| 80306 | <1% | 98 | $198.23 | |
| 97039 | <1% | 37 | $176.96 | |
| 82950 | <1% | 68 | $166.21 | |
| 82784 | <1% | 13 | $160.44 | |
| 85045 | <1% | 70 | $148.56 | |
| 99001 | <1% | 822 | $137.20 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 14 | $133.54 |
| 84300 | <1% | 150 | $125.35 | |
| 86308 | <1% | 33 | $117.42 | |
| 82533 | <1% | 40 | $116.00 | |
| J0571 | Buprenorphine, oral, 1 mg | <1% | 24 | $110.33 |
| 85384 | <1% | 71 | $108.63 | |
| 76882 | <1% | 16 | $108.34 | |
| 89051 | <1% | 28 | $101.14 | |
| 88300 | <1% | 25 | $98.77 | |
| 87807 | <1% | 12 | $86.72 | |
| 84133 | <1% | 109 | $81.43 | |
| 82274 | <1% | 28 | $79.24 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 15 | $79.06 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 59 | $72.95 |
| 85014 | <1% | 118 | $68.46 | |
| 80051 | <1% | 13 | $55.37 | |
| 36591 | <1% | 236 | $52.50 | |
| 84165 | <1% | 14 | $49.59 | |
| 86709 | <1% | 12 | $41.42 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 30 | $38.69 |
| 85018 | <1% | 91 | $37.16 | |
| 83721 | <1% | 15 | $23.28 | |
| 87045 | <1% | 13 | $20.41 | |
| 87076 | <1% | 13 | $18.72 | |
| 87046 | <1% | 13 | $6.76 | |
| 84155 | <1% | 13 | $3.53 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 151 | $0.01 |
| 0637R | 0% | 2,434 | $0.00 | |
| 0259R | 0% | 1,485 | $0.00 | |
| 80320 | 0% | 49 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 106 | $0.00 |
| 96376 | 0% | 104 | $0.00 | |
| 97162 | 0% | 26 | $0.00 | |
| 0370 | 0% | 13 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 15 | $0.00 |
| 84112 | 0% | 58 | $0.00 | |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMPLIN, CHRISTOPHER (PRESIDENT)